TGF beta 2 Antibody - #AF0260

(3)   (8)  
Product: TGF beta 2 Antibody
Catalog: AF0260
Description: Rabbit polyclonal antibody to TGF beta 2
Application: WB IHC
Reactivity: Human, Mouse, Rat
Prediction: Pig, Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 47kDa; 48kD(Calculated).
Uniprot: P61812
RRID: AB_2834159

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MS Report
HPLC Report
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
IHC 1:50-1:200, WB 1:500-1:2000
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat
Prediction:
Pig(100%), Zebrafish(100%), Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(100%), Chicken(100%), Xenopus(88%)
Clonality:
Polyclonal
Specificity:
TGF beta2 Antibody detects endogenous levels of total TGF beta2.
RRID:
AB_2834159
Cite Format: Affinity Biosciences Cat# AF0260, RRID:AB_2834159.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

ARVD; BSC 1 cell growth inhibitor; CED; Cetermin; DPD1; G TSF; Glioblastoma derived T cell suppressor factor; LAP; Latency-associated peptide; Polyergin; TGF beta 1 protein; TGF beta 3; TGF beta1; TGF beta2; TGF beta3; TGF-beta-1; TGFB; tgfb1; TGFB1_HUMAN; TGFB2; TGFB3; TGFbeta; Transforming growth factor; Transforming growth factor beta 1; Transforming growth factor beta 2; Transforming growth factor beta 3;

Immunogens

Immunogen:
Uniprot:

P61812(TGFB2_HUMAN) >>Visit HPA database.

Gene(ID):
TGFB2(7042)
Description:
TGFB2 TGF-beta 2 has suppressive effects on interleukin-2 dependent T-cell growth. Homodimer; disulfide-linked. Heterodimers with TGFB1 and with TGFB3 have been found in bone. Interacts with the serine proteases, HTRA1 and HTRA3. Interacts with ASPN. Belongs to the TGF-beta family. 2 isoforms of the human protein are produced by alternative splicing.
Sequence:
MHYCVLSAFLILHLVTVALSLSTCSTLDMDQFMRKRIEAIRGQILSKLKLTSPPEDYPEPEEVPPEVISIYNSTRDLLQEKASRRAAACERERSDEEYYAKEVYKIDMPPFFPSENAIPPTFYRPYFRIVRFDVSAMEKNASNLVKAEFRVFRLQNPKARVPEQRIELYQILKSKDLTSPTQRYIDSKVVKTRAEGEWLSFDVTDAVHEWLHHKDRNLGFKISLHCPCCTFVPSNNYIIPNKSEELEARFAGIDGTSTYTSGDQKTIKSTRKKNSGKTPHLLLMLLPSYRLESQQTNRRKKRALDAAYCFRNVQDNCCLRPLYIDFKRDLGWKWIHEPKGYNANFCAGACPYLWSSDTQHSRVLSLYNTINPEASASPCCVSQDLEPLTILYYIGKTPKIEQLSNMIVKSCKCS

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Pig
100
Horse
100
Bovine
100
Sheep
100
Dog
100
Zebrafish
100
Chicken
100
Rabbit
100
Xenopus
88
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P61812 As Substrate

Site PTM Type Enzyme
K81 Ubiquitination
Y98 Phosphorylation
K188 Ubiquitination
K333 Ubiquitination
Y341 Phosphorylation
Y352 Phosphorylation
S404 Phosphorylation

Research Backgrounds

Function:

Transforming growth factor beta-2 proprotein: Precursor of the Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains, which constitute the regulatory and active subunit of TGF-beta-2, respectively.

Required to maintain the Transforming growth factor beta-2 (TGF-beta-2) chain in a latent state during storage in extracellular matrix (By similarity). Associates non-covalently with TGF-beta-2 and regulates its activation via interaction with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2 (By similarity).

Transforming growth factor beta-2: Multifunctional protein that regulates various processes such as angiogenesis and heart development. Activation into mature form follows different steps: following cleavage of the proprotein in the Golgi apparatus, Latency-associated peptide (LAP) and Transforming growth factor beta-2 (TGF-beta-2) chains remain non-covalently linked rendering TGF-beta-2 inactive during storage in extracellular matrix (By similarity). At the same time, LAP chain interacts with 'milieu molecules', such as LTBP1 and LRRC32/GARP, that control activation of TGF-beta-2 and maintain it in a latent state during storage in extracellular milieus (By similarity). Once activated following release of LAP, TGF-beta-2 acts by binding to TGF-beta receptors (TGFBR1 and TGFBR2), which transduce signal (By similarity).

PTMs:

Transforming growth factor beta-2 proprotein: The precursor proprotein is cleaved in the Golgi apparatus to form Transforming growth factor beta-2 (TGF-beta-2) and Latency-associated peptide (LAP) chains, which remain non-covalently linked, rendering TGF-beta-2 inactive.

Subcellular Location:

Secreted>Extracellular space>Extracellular matrix.

Secreted.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Subunit Structure:

Interacts with the serine proteases, HTRA1 and HTRA3 (By similarity). Interacts with ASPN. Interacts with MFAP5 (By similarity). Latency-associated peptide: Interacts with Transforming growth factor beta-2 (TGF-beta-2) chain; interaction is non-covalent and maintains (TGF-beta-2) in a latent state (By similarity). Latency-associated peptide: Interacts with LRRC32/GARP; leading to regulate activation of TGF-beta-2. Latency-associated peptide: Interacts with NREP; the interaction results in a decrease in TGFB2 autoinduction (By similarity). Transforming growth factor beta-2: Homodimer; disulfide-linked. Transforming growth factor beta-2: Interacts with TGF-beta receptors (TGFBR1 and TGFBR2), leading to signal transduction (By similarity).

Family&Domains:

Belongs to the TGF-beta family.

Research Fields

· Cellular Processes > Cell growth and death > Cell cycle.   (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence.   (View pathway)

· Environmental Information Processing > Signal transduction > MAPK signaling pathway.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > TGF-beta signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Hippo signaling pathway.   (View pathway)

· Human Diseases > Infectious diseases: Parasitic > Leishmaniasis.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > Malaria.

· Human Diseases > Infectious diseases: Parasitic > Toxoplasmosis.

· Human Diseases > Infectious diseases: Parasitic > Amoebiasis.

· Human Diseases > Infectious diseases: Bacterial > Tuberculosis.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Cancers: Overview > Pathways in cancer.   (View pathway)

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Renal cell carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer.   (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia.   (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma.   (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer.   (View pathway)

· Human Diseases > Immune diseases > Inflammatory bowel disease (IBD).

· Human Diseases > Immune diseases > Rheumatoid arthritis.

· Human Diseases > Cardiovascular diseases > Hypertrophic cardiomyopathy (HCM).

· Human Diseases > Cardiovascular diseases > Dilated cardiomyopathy (DCM).

· Organismal Systems > Development > Osteoclast differentiation.   (View pathway)

References

1). Chelerythrine chloride inhibits the progression of colorectal cancer by targeting cancer-associated fibroblasts through intervention with WNT10B/β-catenin and TGFβ2/Smad2/3 axis. Phytotherapy research : PTR, 2023 (PubMed: 37402476) [IF=7.2]
2). Exosomes Derived from Epidermal Stem Cells Improve Diabetic Wound Healing. Journal of Investigative Dermatology, 2022 (PubMed: 35181300) [IF=6.5]

Application: WB    Species: Human    Sample:

Supplementary Figure S8. ESCs-Exo treatment of FB in vitro activates TGFb and Akt signaling. (a‒c) Expression levels of TGFb1, SMAD2/3, and quantification. (d‒g) Expression levels of TGFb2, TGFb3, pSMAD2/3 (Thr8), and quantification. (h‒k) Expression levels of Akt and pAkt and quantification. n ¼ 3 biological replicates. Data are represented as mean SD; one-way ANOVA with Fisher’s posthoc test. *P < 0.05 versus control and #P < 0.05 versus FB-Exo. Akt, protein kinase B; ESC-Exo, epidermal stem cellederived exosome; FB, fibroblast; FB-Exo, fibroblast-derived exosome; pAkt, phosphorylated protein kinase B; pSMAD, phosphorylated SMAD.
3). Comprehensive upstream and downstream regulatory analyses identify miR-675-3p as a potential prognostic biomarker in melanoma. Human Cell, 2021 (PubMed: 33400243) [IF=4.3]

Application: WB    Species: Human    Sample: melanoma A375 cells

Fig. 7 miR-675-3p may promote cell proliferation, regulate the cell cycle, and activate the TGF-β, HIF-1 signaling pathways. a miR- 675-3p facilitated the G0/G1–G2/M transition in human melanoma A375 cells, b miR-675-3p promoted cell proliferation. c The TGFβ2, Smad2/3, Smad4, and HIF1A protein levels in the TGF-β/SMAD and HIF-1 signaling pathways were signifcantly higher, while TGF β1 was decreased relative to the negative control group

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.